Publicacións en colaboración con investigadores/as de Hospital Universitario Puerta del Mar (10)

2024

  1. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

2022

  1. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

    International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392

2021

  1. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  2. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

    Journal of Clinical Apheresis, Vol. 36, Núm. 4, pp. 563-573

2020

  1. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

2019

  1. Involvement of antifactor VIII autoantibodies specificity in the outcome of inhibitor eradication therapies in acquired hemophilia a patients

    Blood Coagulation and Fibrinolysis, Vol. 30, Núm. 3, pp. 127-132

2013

  1. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)

    Medical Mycology, Vol. 51, Núm. 2, pp. 150-154

2010

  1. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

    European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328

  2. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study

    Transfusion and Apheresis Science, Vol. 43, Núm. 3, pp. 299-303

2001

  1. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: A study of the PETHEMA group

    British Journal of Haematology, Vol. 114, Núm. 1, pp. 99-103